These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 22995373)

  • 1. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours.
    Fauvet R; Dufournet C; Poncelet C; Uzan C; Hugol D; Daraï E
    J Surg Oncol; 2005 Dec; 92(4):337-43. PubMed ID: 16299808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors.
    Zagorianakou N; Stefanou D; Makrydimas G; Zagorianakou P; Briasoulis E; Karavasilis V; Pavlidis N; Agnantis NJ
    Histol Histopathol; 2006 Apr; 21(4):341-7. PubMed ID: 16437378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of p21WAF1/CIP1 and MDM2 characterizes serous borderline ovarian tumors.
    Palazzo JP; Monzon F; Burke M; Hyslop T; Dunton C; Barusevicius A; Capuzzi D; Kovatich AJ
    Hum Pathol; 2000 Jun; 31(6):698-704. PubMed ID: 10872663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of apoptosis related proteins on malignant transformation of ovarian tumors: A comparison between Bcl-2/Bax ratio and p53 immunoreactivity.
    Zeren T; Inan S; Vatansever HS; Sayhan S
    Acta Histochem; 2014 Oct; 116(8):1251-8. PubMed ID: 25108507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.
    Fauvet R; Poncelet C; Hugol D; Lavaur A; Feldmann G; Daraï E
    Virchows Arch; 2003 Jul; 443(1):38-43. PubMed ID: 12756564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of bcl-2, bax, mcl-1, and bcl-X expression in ovarian surface epithelial tumors.
    Wehrli BM; Krajewski S; Gascoyne RD; Reed JC; Gilks CB
    Int J Gynecol Pathol; 1998 Jul; 17(3):255-60. PubMed ID: 9656122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
    Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
    Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
    Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
    O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
    Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
    Sabah M; Cummins R; Leader M; Kay E
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):64-9. PubMed ID: 17536310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
    Arik D; Kulaçoğlu S
    Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.
    Altman AD; Nelson GS; Ghatage P; McIntyre JB; Capper D; Chu P; Nation JG; Karnezis AN; Han G; Kalloger SE; Köbel M
    Mod Pathol; 2013 Sep; 26(9):1255-63. PubMed ID: 23558569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of 103 ovarian serous and mucinous tumors.
    Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
    Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 and related proteins in epithelial ovarian cancer.
    Sengupta PS; McGown AT; Bajaj V; Blackhall F; Swindell R; Bromley M; Shanks JH; Ward T; Buckley CH; Reynolds K; Slade RJ; Jayson GC
    Eur J Cancer; 2000 Dec; 36(18):2317-28. PubMed ID: 11094305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the "SET" feature of high-grade serous carcinoma to the "STEM" feature.
    Hatano Y; Tamada M; Asano N; Hayasaki Y; Tomita H; Morishige KI; Hara A
    Diagn Pathol; 2019 Jan; 14(1):4. PubMed ID: 30636633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors.
    Lee H; Park G; Jung JH; Ahn WS; Lee JM; Kim BK; Kang CS
    Int J Gynecol Cancer; 2005; 15(3):453-61. PubMed ID: 15882169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
    Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
    Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.